Gerlinde Flotzinger

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL). Disruption of its interaction with transcriptional repressors interferes with the oncogenic effects of BCL6. We used a structure-based drug design to develop highly potent compounds that block this interaction. A subset(More)
  • 1